Press Releases and Other News

• December 1st, 2016 – Altravax launches Acclivity Biosystems service division
Acclivity Biosystems, Altravax’s service division, uses directed evolution technologies for custom client programs of protein optimization. With over two decades of expertise with this platform, Altravax has developed the Protein Optimization System™ to facilitate identification of novel and highly functional biosuperior proteins. Through a collaborative process, functional diversity is identified and recombined, generating libraries of candidate proteins. Evaluation using a tiered screening approach results in the identification of proteins conforming to the user-defined target product profile. Recursive rounds of evolution harness the power of combining beneficial changes to gain significant improvements. Functions for evolution include protein expression, activity, specificity, thermostability, or behavior in process-relevant conditions. This technology has broad applicability in the fields of diagnostics, reagents, biological therapeutics, industrial processes, and vaccine development.

• October 31st, 2013 – Altravax announces the appointment of Dr. Sean X. Du as Chief Operating Officer
He joins Altravax from Simcere Pharmaceuticals Group (NYSE:SCR) where he was Executive Director, Institute of Vaccine Research. [More…]

• January 8th, 2013 – Altravax, Inc. awarded $1.2 million to advance dengue vaccine and hepatitis therapeutic
Altravax was awarded two SBIR grants from the NIH’s National Institute of Allergy and Infectious Diseases for research on vaccines to prevent infection by dengue virus and to treat chronic hepatitis B. [More…]

• December 3rd, 2012 – Altravax, Inc. awarded $3.45 million in NIH funds for vaccines to HIV/AIDS
The grant from the NIH’s National Institute of Allergy and Infectious Diseases supports research on antibody‐inducing vaccines for HIV‐1. [More…]

• November 3rd, 2010 – Altravax receives $244,000 Grant under the Affordability Care Act
The grant supports research toward a therapeutic vaccine for chronic hepatitis B infections [More…]

• October 4th, 2010 – Altravax, Inc. Awarded $1.2 million in Federal Funds for Vaccines for HIV/AIDS
MolecularBreeding(TM) technology platform offers potential of broader protection [More…]

February 18, 2010 –  Altravax, Inc. Acquires Revolutionary Technology Platform for Vaccine Development [More…]